Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
264.6 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,828.292 | 1,037.418 | 844.287 | 492.853 | 219.75 | 74.908 | 89.912 | 47.159 | 41.097 | 50.561 | 47.167 | 66.725 | 82.757 | 100.041 | 100.533 | 96.163 | 50.897 | 26.93 | 5.716 | 4.278 | 0.176 | 0 |
| Cost of Revenue
| 310.406 | 168.817 | 140.144 | 78.052 | 25.062 | 1.802 | 13.367 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 1,517.886 | 868.601 | 704.143 | 414.801 | 194.688 | 73.106 | 76.545 | 47.159 | 41.097 | 50.561 | 47.167 | 66.725 | 82.757 | 100.041 | 100.533 | 96.163 | 50.897 | 26.93 | 5.716 | 4.278 | 0.176 | 0 |
| Gross Profit Ratio
| 0.83 | 0.837 | 0.834 | 0.842 | 0.886 | 0.976 | 0.851 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Reseach & Development Expenses
| 1,004.415 | 883.015 | 792.156 | 654.819 | 655.114 | 505.42 | 390.635 | 382.392 | 276.495 | 190.249 | 112.957 | 86.569 | 99.295 | 106.384 | 108.73 | 96.883 | 120.686 | 49.798 | 35.319 | 24.603 | 13.097 | 3.342 |
| General & Administrative Expenses
| 795.646 | 770.658 | 620.639 | 588.42 | 479.005 | 382.359 | 199.365 | 89.354 | 60.61 | 44.526 | 27.152 | 44.612 | 38.28 | 37.727 | 39.914 | 27.115 | 23.388 | 16.633 | 13.869 | 11.939 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 795.646 | 770.658 | 620.639 | 588.42 | 479.005 | 382.359 | 199.365 | 89.354 | 60.61 | 44.526 | 27.152 | 44.612 | 38.28 | 37.727 | 39.914 | 27.115 | 23.388 | 16.633 | 13.869 | 11.939 | 7.527 | 0.88 |
| Other Expenses
| 0 | -109.367 | -2.05 | 45.525 | 20.73 | 4.173 | -3.022 | 6.171 | 0.076 | 1.817 | -0.047 | 0.331 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 1,800.061 | 1,653.673 | 1,412.795 | 1,243.239 | 1,134.119 | 887.779 | 590 | 471.746 | 337.105 | 234.775 | 140.109 | 131.181 | 137.575 | 144.111 | 148.644 | 123.998 | 144.074 | 66.431 | 49.188 | 36.542 | 20.624 | 4.222 |
| Operating Income
| -282.175 | -785.072 | -708.652 | -828.438 | -939.431 | -814.673 | -500.088 | -424.587 | -296.008 | -404.98 | -92.942 | -129.456 | -54.818 | -44.07 | -48.111 | -27.835 | -93.177 | -39.501 | -43.472 | -32.264 | -25.057 | -4.222 |
| Operating Income Ratio
| -0.154 | -0.757 | -0.839 | -1.681 | -4.275 | -10.876 | -5.562 | -9.003 | -7.203 | -8.01 | -1.97 | -1.94 | -0.662 | -0.441 | -0.479 | -0.289 | -1.831 | -1.467 | -7.605 | -7.542 | -142.369 | 0 |
| Total Other Income Expenses Net
| -151.342 | -341.921 | -143.492 | -27.162 | 54.178 | 53.999 | 9.214 | 14.479 | 5.935 | 4.376 | 1.022 | 12.87 | -2.831 | 1.069 | 1.103 | 2.305 | 12.956 | 4.893 | 0.558 | -0.39 | -4.637 | 0 |
| Income Before Tax
| -433.517 | -1,126.993 | -852.144 | -855.6 | -885.253 | -760.674 | -490.874 | -410.108 | -290.073 | -400.604 | -91.92 | -116.586 | -57.649 | -43.001 | -47.008 | -25.53 | -80.221 | -34.608 | -42.914 | -35.367 | -29.694 | 0 |
| Income Before Tax Ratio
| -0.237 | -1.086 | -1.009 | -1.736 | -4.028 | -10.155 | -5.459 | -8.696 | -7.058 | -7.923 | -1.949 | -1.747 | -0.697 | -0.43 | -0.468 | -0.265 | -1.576 | -1.285 | -7.508 | -8.267 | -168.716 | 0 |
| Income Tax Expense
| 6.725 | 4.163 | 0.68 | 2.681 | 0.863 | 0.823 | -25.603 | -23.438 | -24.909 | -40.209 | -2.695 | -10.572 | -5.799 | 0.514 | 0.582 | 0.719 | 5.245 | -4.893 | -0.558 | 0.39 | 4.585 | -0.086 |
| Net Income
| -440.242 | -1,131.156 | -852.824 | -858.281 | -886.116 | -761.497 | -490.874 | -410.108 | -290.073 | -360.395 | -89.225 | -106.014 | -57.649 | -43.515 | -47.59 | -26.249 | -85.466 | -34.608 | -42.914 | -32.654 | -25.033 | -4.136 |
| Net Income Ratio
| -0.241 | -1.09 | -1.01 | -1.741 | -4.032 | -10.166 | -5.459 | -8.696 | -7.058 | -7.128 | -1.892 | -1.589 | -0.697 | -0.435 | -0.473 | -0.273 | -1.679 | -1.285 | -7.508 | -7.633 | -142.233 | 0 |
| EPS
| -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EPS Diluted
| -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EBITDA
| -258.242 | -926.557 | -661.556 | -736.332 | -868.078 | -754.239 | -488.19 | -409.457 | -276.958 | -172.288 | -82.713 | -51.714 | -49.693 | -38.06 | -41.016 | -18.932 | -75.056 | -35.686 | -38.826 | -29.549 | -19.61 | -4.186 |
| EBITDA Ratio
| -0.141 | -0.862 | -0.84 | -1.565 | -4.275 | -11.15 | -5.562 | -9.003 | -7.203 | 0.723 | -1.97 | -0.233 | -0.656 | -0.505 | -0.474 | -0.236 | -1.745 | -1.316 | -7.056 | -6.916 | -85.074 | 0 |